Comparing Vildagliptin and Metformin for treating Polycystic Ovary Syndrome
Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome: A Randomized Clinical Trial
This study is testing whether Vildagliptin or Metformin works better to help women with Polycystic Ovary Syndrome manage their symptoms.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | Female |
| Sponsor | October 6 University Academic / other |
| Locations | 1 site (Giza) |
| Trial ID | NCT06142656 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the efficacy of Vildagliptin compared to Metformin in women diagnosed with Polycystic Ovary Syndrome (PCOS). The study aims to determine which medication is more effective in managing symptoms associated with PCOS, a condition that affects a significant number of women of reproductive age. Participants will be women who meet specific diagnostic criteria for PCOS, and they will receive either Vildagliptin or Metformin as part of the intervention. The trial is designed to assess the outcomes related to symptom relief and overall management of PCOS.
Who should consider this trial
Good fit: Ideal candidates for this study are women diagnosed with PCOS according to established criteria.
Not a fit: Patients with a history of diabetes mellitus or other specified exclusion criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a more effective pharmacological treatment option for women suffering from PCOS.
How similar studies have performed: While pharmacological treatments for PCOS have been explored, this specific comparison of Vildagliptin and Metformin is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: -Women diagnosed with PCOS according to Rotterdam 2003 criteria National Institute of Health criteria. Exclusion Criteria: * Patients with history of diabetes mellitus (Type 1 or 2). * Patients with liver or renal dysfunction; inflammatory diseases; autoimmune disease; cancer, acute cardiovascular event within last three months * Known hypersensitivity or contraindications to use dipeptidyl peptidase-4 (DPP-4) inhibitors * Eating disorders (anorexia, bulimia) or gastrointestinal disorders
Where this trial is running
Giza
- October 6 university hospital — Giza, Egypt (Recruiting)
Study contacts
- Principal investigator: ahmed hussein, PhD — october 6 university hospital
- Study coordinator: ahmed hussein, phD
- Email: ahmedhussein.med@o6u.edu.eg
- Phone: 01001749605
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.